March Biosciences is developing advanced cell therapies, targeting complex diseases like cancer and genetic disorders through precision medicine approaches. Their lead asset, MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells.

Latus Bio is developing curative medicines for neurological diseases, enabled by unprecedented AAV capsids that unlock new possibilities for patient care.

Rubedo discovers and develops medicines to keep you biologically young by targeting the pathologic cells that drive aging.

Developing the next generation of induced-proximity medicines